Purpose
To assess the effects of a heart rate-moderating calcium channel blocker (verapamil SR), an angiotensin converting enzyme
(ACE) inhibitor (trandolapril) and their combination on the incidence of microalbuminuria (Phase A: primary prevention) and of
macroalbuminuria (Phase B: secondary prevention) in hypertensive NIDD patients.
References
Ruggenenti P, et al & Remuzzi G, on behalf of the Bergamo Diabetic Nephropathy Study Group: Primary prevention of renal
failure in diabetic patients: the Bergamo Nephrologic Diabetes Complication Trial. Am J Hypertens Suppl 1998,
16:S95-S97. |
Farmacêutica